I
Isabel Muehlen-Bartmer
Publications - 14
Citations - 765
Isabel Muehlen-Bartmer is an academic researcher. The author has contributed to research in topics: Insulin glargine & Type 2 diabetes. The author has an hindex of 7, co-authored 13 publications receiving 681 citations.
Papers
More filters
Journal ArticleDOI
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
Matthew C. Riddle,Geremia B. Bolli,Monika Ziemen,Isabel Muehlen-Bartmer,Florence Bizet,Philip Home +5 more
TL;DR: Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.
Journal ArticleDOI
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension
Hannele Yki-Järvinen,Hannele Yki-Järvinen,Richard M. Bergenstal,Geremia B. Bolli,Monika Ziemen,Marek Wardecki,Isabel Muehlen-Bartmer,M. Maroccia,Matthew C. Riddle +8 more
TL;DR: To compare the efficacy and safety of new insulin glargine 300 U/ml (Gla‐300) with insulinglargine 100 U/ ml (Glo‐100) over 12 months of treatment in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (OADs).
Journal ArticleDOI
One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension
Matthew C. Riddle,Hannele Yki-Järvinen,Geremia B. Bolli,Monika Ziemen,Isabel Muehlen-Bartmer,S. Cissokho,Philip Home +6 more
TL;DR: To evaluate the maintenance of efficacy and safety of insulinglargine 300 U/ml (Gla‐300) versus glargine 100 U/ML (Glo‐100) in people with type 2 diabetes mellitus (T2DM) using basal plus meal‐time insulin for 12 months in the EDITION 1 trial.
Journal ArticleDOI
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M. Bergenstal,Timothy S. Bailey,David Rodbard,Monika Ziemen,Hailing Guo,Isabel Muehlen-Bartmer,Andrew J. Ahmann +6 more
TL;DR: Less increase in CGM-based glucose levels in the last 4 h of the 24-h injection interval, smoother average 24-H glucose profiles irrespective of injection time, and reduced nocturnal hypoglycemia were observed with Gla-300 versus Gla -100.
Journal ArticleDOI
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
Matthew C. Riddle,Geremia B. Bolli,Philip Home,Richard M. Bergenstal,Monika Ziemen,Isabel Muehlen-Bartmer,Marek Wardecki,L. Vinet,Nathalie Jeandidier,Hannele Yki-Järvinen +9 more
TL;DR: The efficacy and safety of Gla-300 demonstrated in EDITION 1 and EDITION 2 are maintained in substudies when the insulin was injected up to 3 h before or after the usual time of administration.